Literature DB >> 11050421

The biology and analysis of single disseminated tumour cells.

C A Klein1.   

Abstract

Despite an increasing molecular-genetic understanding of the development of malignant epithelial neoplasias, the frontline therapy for patients with carcinomas is still surgery. Systemic adjuvant treatments such as chemotherapy or immunotherapy have had limited success perhaps because they are based on analysis of the primary tumour or on cell lines derived from metastasis. However, the characteristics of systemically disseminated tumour cells can be very different from that of the primary tumour or end-stage metastasis. Consequently, there is a need to study the evolution and nature of systemic cancer directly in order to identify new target structures for therapy present on the potential precursors of metastasis--the disseminated tumour cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11050421     DOI: 10.1016/s0962-8924(00)01846-8

Source DB:  PubMed          Journal:  Trends Cell Biol        ISSN: 0962-8924            Impact factor:   20.808


  3 in total

1.  Optical imaging of cancer metastasis to bone marrow: a mouse model of minimal residual disease.

Authors:  Antoinette Wetterwald; Gabri van der Pluijm; Ivo Que; Bianca Sijmons; Jeroen Buijs; Marcel Karperien; Clemens W G M Löwik; Elsbeth Gautschi; George N Thalmann; Marco G Cecchini
Journal:  Am J Pathol       Date:  2002-03       Impact factor: 4.307

2.  Immunomagnetic isolation and in vitro expansion of human uveal melanoma cell lines.

Authors:  Jonathan J Cools-Lartigue; Cristin S McCauley; Jean-Claude A Marshall; Sebastian Di Cesare; Francois Gregoire; Emilia Antecka; Patrick Logan; Miguel N Burnier
Journal:  Mol Vis       Date:  2008-01-10       Impact factor: 2.367

3.  Evidence for liver and peripheral immune cells secreting tumor-suppressive extracellular vesicles in melanoma patients.

Authors:  Jung-Hyun Lee; Martin Eberhardt; Katja Blume; Julio Vera; Andreas S Baur
Journal:  EBioMedicine       Date:  2020-11-23       Impact factor: 8.143

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.